文献速递艾滋病与性传播感染

健康哺乳期无HIV女性母乳中比克替拉韦浓度研究

Bictegravir concentrations in breastmilk of healthy, lactating women without HIV.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

INTRODUCTION: Risk of transmission of HIV through breastfeeding is minimal in case of maternal viral suppression due to antiretroviral therapy. However, to what extent antiretroviral drugs transfer into breastmilk is not fully understood.…

要点

  • 母乳中比克替拉韦浓度极低,母乳/血浆比值几何均值0.009
  • 婴儿相对剂量低于1%,预期不会导致婴儿毒性
  • 单次给药数据,需考虑新生儿代谢能力未完全发育

核心结论

  • 经母乳暴露于比克替拉韦非常低,相对婴儿剂量低于1%,即使新生儿代谢能力未完全发育,预期不会引起婴儿毒性。

主要发现

  • 血浆AUC几何均值(CV%)为52.17(22.6)mg*h/L,母乳为0.44(32.0)mg*h/L,母乳/血浆比值几何均值(CV%)为0.009(26.6)。
  • 按150或200 mL/kg/day摄入量,婴儿每日剂量中位数(IQR)分别为0.034 mg/kg/day(0.026-0.060)和0.046(0.035-0.080)mg/kg/day。
  • 相对婴儿剂量中位数(IQR)分别为0.68(0.53-1.00)%和0.90%(0.71-1.33)。

临床怎么用

  • 对于接受比克替拉韦治疗的哺乳期HIV感染者,母乳中药物浓度极低,婴儿相对剂量低于1%,支持母乳喂养时婴儿药物暴露风险很小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Risk of transmission of HIV through breastfeeding is minimal in case of maternal viral suppression due to antiretroviral therapy. However, to what extent antiretroviral drugs transfer into breastmilk is not fully understood. Data are especially lacking for relatively newer drugs-such as bictegravir-that only recently was approved to use in pregnancy. Therefore, the aim of this study is to determine infant exposure to bictegravir through breastmilk. MATERIALS AND METHODS: Concentrations of bictegravir were measured in plasma and breastmilk of healthy, lactating women without HIV after a single dose of bictegravir 50 mg (co-formulated with tenofovir alafenamide 25 mg and emtricitabine 200 mg). Concentrations were measured using validated LC-MS/MS assays and pharmacokinetic parameters were calculated using non-compartmental analysis. Breastmilk to maternal plasma ratio, daily infant dosage and relative infant dose were established to determine infant exposure to bictegravir through breastmilk. RESULTS: Twelve volunteers participated in the study. The geometric mean (CV%) area under the curve based on the last measured concentration was 52.17 (22.6) mg*h/L in plasma and 0.44 (32.0) mg*h/L in breastmilk, resulting in a geometric mean (CV%) breastmilk to maternal plasma ratio of 0.009 (26.6). The median (IQR) daily infant and relative infant doses with an intake of 150 or 200 mL/kg/day were 0.034 mg/kg/day (0.026-0.060) and 0.046 (0.035-0.080) mg/kg/day and 0.68 (0.53-1.00) % and 0.90% (0.71-1.33), respectively. CONCLUSION: Exposure to bictegravir through breastmilk is very low, with a relative infant dose below 1%. Even though metabolizing capacity in newborns is not yet fully developed, it is not expected to cause infant toxicity.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. van der Wekken-Pas LC, van Leeuwen E, van Ewijk-Beneken Kolmer EWJ, et al. Bictegravir concentrations in breastmilk of healthy, lactating women without HIV. J Antimicrob Chemother. 2026. PMID: 41628196. doi:10.1093/jac/dkag022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。